**Ménière's Disease Treatment**

[29] Claes GM, De Valck CFJ, Van de Heyning P, Wuyts FL. Does 'Cochlear Ménière's Disease' exist? An electrocochleographic and audiometric study. Audiology and Neurotology.

[30] Belinchon A, Perez‐Garrigues H, Tenias JM. Evolution of symptoms in Ménière's dis‐

[31] Figueiredo RR, Azevedo AA, Penido NO. Pharmacological treatment of tinnitus. In. Watson J,editor. Tinnitus Epidemiology, Causes and Emerging Therapeutic Treatments.

[32] Langguth B, Salvi R, Elgoyhen AB. Emerging pharmacotherapy of tinnitus. Expert Opinion and Emerging Drugs. 2009;**14**(4):687‐702. DOI: 10.1517/14728210903206975 [33] Ganança MM, Caovilla HH, Gazzola JM, Ganança CF, Ganança FF. Betahistine in the treatment of tinnitus in patients with vestibular disorders. Brazilian journal of otorhino‐

[34] Lezius F, Adrion C, Mansmann U, Jahn K, Strupp M. High dosage betahistine dihydro‐ chloride between 288 and 480 mg/day in patients with severe Ménière's disease: A case series. European Archives of Otorhinolaryngology. 2011;**268**(8):1237‐1240.DOI: 10.1007/

[35] Azevedo, A, Figueiredo RR, Schlee W. Immediate effects of nasal oxytocin in tinnitus patients. In: Annals of the 10th International Tinnitus Research Initiative Conference; 16‐18 March 2016; Nottingham, England. Nottingham: Tinnitus Research Initiative;

[36] Mick P, Amoodi H, Arnoldner C, Shipp D, Friesen L, Lin V et al. Cochlear implantation in patients with advanced Ménière's disease. Otology Neurotology. 2014;**35**(7):1172‐

ease. Audiology Neurotology. 2012;**17**:126‐132. DOI: 10.1159/000331945

2013;**18**:63‐70. DOI: 10.1159/000342686

158 Up to Date on Meniere's Disease

laryngology. 2011;**77**(4):499‐503

1178. DOI: 10.1097/MAO0000000000000202

s00405‐011‐1647‐2

2016.pp 61‐62

New York: Nova Science Publishers; 2016.pp 25‐42

**Chapter 12**
